ReviewTranslational andrology and urology2013
Current clinical challenges in prostate cancer.
Review in Translational andrology and urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- NF-κB Signaling in Prostate Cancer Progression: Inflammatory Mediators, Survival Pathways, and Regulatory Axes.Cancers · 2026Review
- Article
- ANGPTL4: A Comprehensive Review of 25 Years of Research.Cancers · 2025Review
- Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions.International journal of molecular sciences · 2025Review
- Integrative genomic analysis identifiesFrontiers in pharmacology · 2025Article
- Review
- Factors Guiding Clinical Decision-Making in Genitourinary Oncology.Cancer medicine · 2024Review
- Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.Journal of clinical medicine · 2024Article
- Melatonin and Prostate Cancer: Anti-tumor Roles and Therapeutic Application.Aging and disease · 2023Review
- The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.Medical sciences (Basel, Switzerland) · 2022Review
- Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research.British journal of cancer · 2022Review
- Concordance of MRI-Guided Fusion and Systematic 12-Core Prostate Biopsy for the Detection of Prostate Cancer.Frontiers in oncology · 2022Article
- Differential Expression of E2F Transcription Factors and Their Functional and Prognostic Roles in Human Prostate Cancer.Frontiers in cell and developmental biology · 2022Article
- Proteomic Analysis Identifies NDUFS1 and ATP5O as Novel Markers for Survival Outcome in Prostate Cancer.Cancers · 2021Article
- Factors predicting biochemical response and survival benefits following radioligand therapy with [European journal of nuclear medicine and molecular imaging · 2021Review
- Overexpression of SOX4 induces up-regulation of miR-126 and miR-195 in LNCaP prostate cancer cell line.Cytotechnology · 2020Article
- Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities.Cold Spring Harbor perspectives in medicine · 2019Review
- Metabolomics Biomarkers of Prostate Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2019Review
- Targeting Splicing in Prostate Cancer.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common malignancy and the second leading cause of cancer death in men in the United States. Close to $12 billion are spent annually on the treatment of prostate cancer in the US alone. Yet still there remain tremendous controversies and challenges that exist in all facets of the disease. This review and discussion will focus on issues and challenges for clinicians and patients diagnosed with the disease. Appropriate risk stratification for men with newly diagnosed prostate cancer is an appropriate first step for all patients. Once risk-stratified, for those with low-risk of death, it is increasingly recognized that overtreatment creates an unnecessary burden for many patients. This is particularly evident when put in the context of competing comorbidities in an elderly population. For those with advanced or high-risk localized disease, under-treatment remains too common. For those with a high-risk of recurrence or failure following primary treatment, adjuvant or salvage therapies are an option, but how and when to best deploy these treatments are controversial. Recently, tremendous progress has been made for those with advanced disease, in particular those with metastatic castrate-resistant prostate cancer (mCRPC). Within the last 4 years, five novel FDA approved agents, acting through distinct mechanisms have been FDA approved for mCRPC. With the introduction of these new agents a host of new challenges have arisen. Timing, sequencing and combinations of these novel agents are welcomed challenges when compared with the lack of available therapies just a few years ago. In this summary of current clinical challenges in prostate cancer we review critical recent studies that have created or shifted the current paradigms of treatment for prostate cancer. We will also highlight ongoing issues that continue to challenge our field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.